Christopher S. Boerner
Net Worth
Last updated:
What is Christopher S. Boerner net worth?
The estimated net worth of Dr. Christopher S. Boerner is at least $20,752,162 as of 14 Mar 2022. He owns shares worth $2,028,636 as insider, has earned $2,043,526 from insider trading and has received compensation worth at least $16,680,000 in Bristol-Myers Squibb Company.
What is the salary of Christopher S. Boerner?
Dr. Christopher S. Boerner salary is $2,780,000 per year as Executive Vice President & Chief Commercialization Officer in Bristol-Myers Squibb Company.
How old is Christopher S. Boerner?
Dr. Christopher S. Boerner is 54 years old, born in 1971.
What stocks does Christopher S. Boerner currently own?
As insider, Dr. Christopher S. Boerner owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | Executive Vice President & Chief Commercialization Officer | 41,966 | $48.34 | $2,028,636 |
What does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Christopher S. Boerner insider trading
Bristol-Myers Squibb Company
Dr. Christopher S. Boerner has made only one insider trade between 2019-2022, according to the Form 4 filled with the SEC. He sold 29,532 units of BMY stock worth $2,043,526 on 14 Mar 2022.
As of 14 Mar 2022 he still owns at least 41,966 units of BMY stock.
Bristol-Myers Squibb Company key executives
Bristol-Myers Squibb Company executives and other stock owners filed with the SEC:
- Dr. Christopher S. Boerner (54) Executive Vice President & Chief Commercialization Officer
- Dr. Giovanni Caforio (60) Chairman & Chief Executive Officer
- Mr. David V. Elkins (57) Executive Vice President & Chief Financial Officer
- Mr. Rupert Vessey M.A. (60) Executive Vice President and Pres of Research & Early Devel.
- Ms. Sandra Leung Esq. (64) Executive Vice President & Gen. Counsel